GLP-1 Agonists

Dr. Andrew Huberman Favorable — Covers Science Extensively

Huberman covers GLP-1 agonists across multiple contexts: hunger neuroscience, peptide therapy, and fat loss protocols. He features Dr. Zachary Knight (UCSF) explaining the mechanism of GLP-1 drugs, their origin from Gila monster venom, and the evolution from short-acting to long-acting forms. He discusses how GLP-1 acts on brain stem and hypothalamic circuits to suppress appetite. In peptide therapy episodes, Dr. Craig Koniver discusses micro-dosing semaglutide and tirzepatide to mitigate side effects. Huberman also frequently mentions yerba mate as a natural GLP-1 stimulator for fat loss.

…significantly. There are also nowadays drugs which are called analogues of GLP-1. So these are drugs that mimic or are identical to the kind of GLP-1 that you would make. And those drugs are proven to be very effective for the treatment of certain forms of diabetes and for the treatment of obesity, but they trigger enormous amounts of GLP-1 pathway activation. So those are extreme cases for people that are really struggling for weight loss. But the clinical trials and the data that are out there in the general population now are very, very promising for GLP-1 analogues.

▶ 05:15 · Using Caffeine to Optimize Mental & Physical Performance | Huberman Lab Podcast 101

3 more clips

• 75:02 · The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight (Guest: Zachary Knight)
• 00:34 · Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver (Guest: Craig Koniver)
• 14:05 · Lose Fat With Science-Based Tools | Huberman Lab Essentials

Dr. Peter Attia Strongly Favorable with Caveats

Attia is the most comprehensive source on GLP-1 agonists, with multiple dedicated episodes spanning mechanism of action, clinical trial analysis, dosing, and evolving perspectives. He provides a detailed breakdown of the incretin effect, explains semaglutide versus tirzepatide pharmacology, and dedicates significant time to the muscle loss concern — which he calls alarming. He critiques the FDA for ignoring body composition in weight loss studies and advises long-term use with high protein and strength training. He also explores GLP-1 agonists as potential geroprotective agents and discusses their cardiovascular benefits.

…seems to do so safely there are have been no shortage of other drugs in the past that have suppressed appetite but they have done so with some really negative side effects for example some of them are stimulants you've got of course fenfen which is its own category of potential damage this drum Works centrally and it works really effectively it also has the benefit of improving glycemic control and it does that quite effectively as well in fact the first iterations of semaglutide were used in patients with type 2 diabetes it's been rebranded as wagovia uh as a as a drug for weight loss and it's dosed slightly differently…

▶ 01:28 · Cause for caution with weight loss drugs like Ozempic | Peter Attia, M.D.

5 more clips

• 12:30 · Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent
• 01:07 · New insights on GLP-1 agonists — Ozempic, Wegovy, Mounjaro, and more
• 01:15 · GLP-1 Agonists: The Future of Treating Obesity?
• 01:37 · GLP-1 agonists and the willpower myth
• 05:07 · GLP-1 agonists in bodybuilding and weight management: moral and philosophical implications (Guest: Mike Israetel)

Dr. Rhonda Patrick Limited Direct Coverage

Patrick's analyzed videos contain only indirect GLP-1 coverage through a guest appearance by Dr. Ben Bikman, who discusses GLP-1 agonists in the context of insulin resistance reversal. Dr. Bikman acknowledges that semaglutide can be effective for weight loss and improving metabolic health by delaying gastric emptying and activating satiety centers, but raises concerns about high doses potentially causing muscle catabolism and negative mental health effects. Patrick herself does not offer a direct stance on GLP-1 medications in the analyzed content.

1 more clip

• 17:47 · Dr. Ben Bikman: How To Reverse Insulin Resistance Through Diet, Exercise, & Sleep (Guest: Ben Bikman)

Bryan Johnson Limited Direct Coverage

Johnson's analyzed videos contain only tangential GLP-1 coverage. In his podcast with Dr. Mike Israetel, the guest acknowledges that GLP-1 agonists are revolutionizing weight management as anti-obesity drugs, but the discussion does not explore Johnson's personal stance or protocol regarding these medications. His Blueprint protocol, focused on data-driven supplement stacks and lifestyle optimization, does not explicitly incorporate GLP-1 agonists.

1 more clip

• 07:45 · The Future of Fitness: Dr. Mike Israetel on AI, Steroids & Online Criticism | Bryan Johnson Podcast (Guest: Mike Israetel)

Dr. Mark Hyman Strongly Opposes Widespread Use

Hyman is the most vocal critic of GLP-1 agonists among all five experts, with multiple dedicated videos arguing against their widespread use. He highlights serious risks including gastroparesis, bowel obstruction, pancreatitis, and significant lean muscle mass loss. He critiques the pharmaceutical industry's focus on creating lifelong drug dependency rather than addressing root causes, and estimates that 93% of Americans are metabolically unhealthy due to a toxic food environment — a systemic problem that drugs cannot fix. He is particularly alarmed by the prospect of prescribing these medications to children. His functional medicine framework emphasizes nutrient-dense whole foods, adequate protein, fiber, sleep, and resistance training as the sustainable path to metabolic health.

6 more clips

• 01:22 · Ozempic For Weight Loss - Here's Why You Shouldn't Take It For Longevity
• 04:11 · Ozempic For Weight Loss - Here's Why You Shouldn't Take It For Longevity
• 13:31 · The SHOCKING Truth About Ozempic Side Effects (And How To Avoid Them) (Guest: Tina)
• 42:23 · The Shocking TRUTH About Diabetes and Food
• 12:14 · The BIGGEST PROBLEMS With Losing Weight In Today's Society & Why It's SO HARD
• 15:22 · Are We Overmedicating? Big Pharma's Hidden Dangers | Dr. Marty Makary (Guest: Marty Makary)

What do experts agree on about glp-1 agonists?

This is one of the most polarizing topics across our expert panel. Attia and Huberman see GLP-1 agonists as powerful tools when combined with exercise and high protein intake, while Hyman strongly opposes their widespread use, arguing they mask root causes and create pharmaceutical dependency.

Where do the experts disagree on glp-1 agonists?

Attia views GLP-1 agonists as powerful, appropriate tools for weight management when combined with exercise and nutrition — while Hyman argues they mask root causes, create lifelong pharmaceutical dependency, and do not address the toxic food environment driving metabolic disease. Attia's position on GLP-1s has evolved significantly over time and he now sees them more favorably, while Hyman has become increasingly critical, particularly regarding their use in children and as a substitute for dietary intervention. On the question of muscle loss: Attia acknowledges it as a serious but manageable risk with proper protein and training protocols, while Hyman and Patrick's guest (Dr. Bikman) frame it as a fundamental problem that undermines the drugs' value.

How strong is the expert consensus on glp-1 agonists?

The consensus on glp-1 agonists scores 2.6/5 — a moderate level of agreement across Huberman, Attia, Patrick, Johnson, and Hyman, based on their public videos.